Alan Davidson, DO
Family Medicine · Hutchinson, KSNPI 1245339126
Payments from drug & device makers
Across 625 payments — averaging $13.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1K
- AbbVie$1K
- Novo Nordisk$965
- AstraZeneca$848
- Lilly USA, LLC$799
- Amgen$482
- plus $3K from 32 others
What the payments were for
- Food & beverage$8,293100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 113 | $1,167 |
| AbbVie(2 entities) | 135 | $1,136 |
| Novo Nordisk | 80 | $965 |
| AstraZeneca | 31 | $848 |
| Lilly USA, LLC | 59 | $799 |
| Amgen | 29 | $482 |
| Sanofi-aventis U.S. LLC | 30 | $414 |
| Boehringer Ingelheim | 16 | $257 |
| Exact Sciences | 15 | $242 |
| Paratek Pharmaceuticals, Inc. | 12 | $219 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $204 |
| GSK | 13 | $200 |
| Abbott | 10 | $165 |
| Sumitomo Pharma America, Inc. | 6 | $115 |
| Amarin Pharma, Inc. | 6 | $112 |
| Johnson & Johnson | 6 | $79 |
| Dexcom, Inc. | 4 | $75 |
| Astellas Pharma US Inc | 5 | $69 |
| Novartis | 3 | $68 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $67 |
| Radius Health, Inc. | 4 | $66 |
| Daiichi Sankyo Inc. | 4 | $63 |
| Xeris Pharmaceuticals, Inc. | 3 | $59 |
| Bayer | 4 | $56 |
| Supernus Pharmaceuticals, Inc. | 2 | $40 |
| Mylan Specialty L.p. | 1 | $40 |
| Merck | 3 | $39 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Phathom Pharmaceuticals, Inc. | 2 | $26 |
| Circassia Inc. | 1 | $22 |
| Eisai Inc. | 1 | $20 |
| Upsher-smith Laboratories LLC | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Verona Pharma, Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,293 in reported general payments places this provider in the 90th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 136 | $152,331 |
| JanuviaSitagliptin Phosphate | 65 | $52,310 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 57 | $43,186 |
| EliquisApixaban | 52 | $41,290 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $17,464 |
| Repatha SureclickEvolocumab | 22 | $12,134 |
| XareltoRivaroxaban | 16 | $11,035 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 24 | $6,101 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 57 | $5,957 |
| Gabapentin | 368 | $5,740 |
| Humalog Kwikpen U-100Insulin Lispro | 31 | $5,354 |
| Levothyroxine Sodium | 627 | $4,986 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,910 |
| Pantoprazole Sodium | 493 | $3,949 |
| Novolog FlexpenInsulin Aspart | 15 | $3,527 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $965 | $152,331136 claims |
| MerckJanuvia | $39 | $52,31065 claims |
| PfizerEliquis, Paxlovid | $1,167 | $42,71968 claims |
| Johnson & JohnsonXarelto | $79 | $11,03516 claims |
| GSKBreo Ellipta | $200 | $4,91012 claims |
| Sanofi-aventis U.S. LLCLantus | $414 | $1,50718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Hutchinson
- Geri HartHutchinson$48K
- Terry PolingWichita$24.2M
- Richard GloverNewton$19.6M
- Daniel DickersonLenexa$13.6M
- Patrick YaoOlathe$11.7M
- Michael RauschAugusta$8.1M
- Terry KleinWichita$5.9M
- Richard EgelhofWichita$4.1M
- Thomas KleinWichita$3.4M
- Troy HoldemanNewton$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.